| Target Molecule | Vasopressin |
| Synonyms | Arginine vasopressin (AVP), Argipressin, Antidiuretic hormone (ADH) |
| CAS Number | 11000-17-2 (arginine vasopressin); 113-79-1 |
| Sequence (3-Letter) | H-Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH₂ (cyclic Cys1–Cys6 disulfide) |
| Sequence (1-Letter) | CYFQNCPRG-NH₂ |
| Molecular Formula | C₄₆H₆₅N₁₅O₁₂S₂ |
| Molecular Weight | 1084.23 |
| Service Category | Custom Peptide Synthesis / CDMO Manufacturing |
| Synthesis Purity | Customizable (e.g., ≥98%, ≥99% via HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Acetate (standard pharmaceutical salt), TFA, or custom options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) and Directed Oxidative Folding |
| Modification Options | Intramolecular disulfide bridging, C-terminal amidation, stable isotope labeling, structural analogue synthesis (Desmopressin, Terlipressin) |
| Available Scale | Milligram (R&D) to Kilogram (Commercial CDMO) |
| Analytical Data | Comprehensive COA, HPLC, MS, and disulfide connectivity verification provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, analytical development, and industrial formulation. Not a finished medicine. |
Vasopressin (arginine vasopressin, CAS 11000-17-2) is a cyclic nonapeptide hormone requiring a precise Cys1-Cys6 intramolecular disulfide bridge and C-terminal amidation. We target this sequence to supply high-purity reference materials, analytical standards, and raw materials for cardiovascular and neuroendocrine research.
We utilize optimized solid-phase peptide synthesis (SPPS) and directed oxidative folding techniques. Our peptide synthesis platform ensures complete chain elongation and precise ring closure between Cys1 and Cys6, preventing linear precursors and polymeric aggregation.
Yes. We provide extensive peptide modification services for vasopressin-related sequences. Capabilities include the synthesis of structural analogues such as Desmopressin and Terlipressin, site-specific stable isotope labeling (13C, 15N) for quantitative mass spectrometry, and impurity profiling standards.
Our manufacturing infrastructure scales production from milligram-level analytical batches to multigram and kilogram commercial quantities. We optimize preparative HPLC purification and controlled counter-ion exchange (such as TFA removal to acetate) to ensure strict batch-to-batch consistency.
We operate as an integrated technical partner providing complete peptide CDMO solutions. Our team manages sequence optimization, disulfide verification, impurity profiling, analytical method validation, and regulatory documentation to advance complex drug development pipelines.
Vasopressin, also recognized as arginine vasopressin (AVP) or antidiuretic hormone (ADH), is a natural cyclic nonapeptide defined by the sequence CYFQNCPRG-NH2 with a Cys1–Cys6 disulfide bridge. Synpeptide provides comprehensive custom synthesis solutions for this molecule. Constructing this constrained cyclic sequence demonstrates our advanced technical capabilities in controlled oxidative folding, disulfide constraint, and CDMO manufacturing.
Assembling the 9-residue cyclic sequence requires high-fidelity sequence elongation followed by meticulous intramolecular cyclization between Cys1 and Cys6. Our custom peptide synthesis platform utilizes optimized Solid-Phase Peptide Synthesis (SPPS) protocols, sequence-specific resin selection, and directed oxidative folding techniques to ensure exact stereochemical fidelity and high-yield ring closure.
Vasopressin serves as the parent structure for a critical family of therapeutic analogues. Through our peptide modification services, we routinely synthesize related sequences such as Desmopressin and Terlipressin. We also provide stable isotope labeling (13C, 15N) for quantitative bioanalysis and synthesize specific linear precursors or structural variants as critical impurity reference standards.
Transitioning a cyclic nonapeptide from laboratory screening to commercial production requires robust downstream processing. The high-dilution conditions required to prevent intermolecular oligomerization during cyclization demand specialized engineering. We execute large-scale peptide synthesis for Vasopressin using continuous-flow oxidation systems and high-capacity preparative HPLC purification, scaling seamlessly from milligram research batches to kilogram commercial lots with verified batch-to-batch consistency.
We deliver comprehensive technical support as a fully integrated peptide CDMO. Our technical teams assist pharmaceutical developers through process optimization, rigorous stability assessments, analytical method validation, and complete regulatory documentation. We provide the precise data and scalable manufacturing required to advance complex cyclic peptide APIs through the development lifecycle.
